Add to ORKGIntroduction. Lung cancer is currently the most common malignancy (1.6 million new cases annually...
Aim: To evaluate treatment patterns and overall survival (OS) in real world metastatic non-squamous ...
The discovery of EGFR tyrosine kinase inhibitors (TKI) for the treatment of EGFR mutant (EGFRm) meta...
Lung cancer accounts for a quarter of all mortality cases worldwide. To date, numerous efforts have ...
Molecularly targeted therapies, which can be used in genetically selected patients, play an increasi...
none20Lung cancer is the most common cancer in the world today, in terms of both incidence and morta...
Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. The last few years ha...
In the past decade the advent of target therapy has led to a silent revolution in the treatment of l...
Introduction. Lung cancer is the most common cancer in the world. Every year, there are over 1.4 m...
Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. The last few years ha...
Trabalho Final do Mestrado Integrado em Medicina apresentado à Faculdade de MedicinaIntrodução: A de...
The disappointing results of long-term survival among patients with non-small cell lung cancer (NSCL...
AbstractWe report here a 66-year-old woman diagnosed with bronchioloalveolar carcinoma of the right ...
PURPOSE: Immune checkpoint inhibitors (ICI) have shown marked responses in patients with non-small c...
Objectives: Molecular diagnostics and care of non-small cell lung cancer (NSCLC) are continuously ev...
Introduction. Lung cancer is currently the most common malignancy (1.6 million new cases annually...
Aim: To evaluate treatment patterns and overall survival (OS) in real world metastatic non-squamous ...
The discovery of EGFR tyrosine kinase inhibitors (TKI) for the treatment of EGFR mutant (EGFRm) meta...
Lung cancer accounts for a quarter of all mortality cases worldwide. To date, numerous efforts have ...
Molecularly targeted therapies, which can be used in genetically selected patients, play an increasi...
none20Lung cancer is the most common cancer in the world today, in terms of both incidence and morta...
Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. The last few years ha...
In the past decade the advent of target therapy has led to a silent revolution in the treatment of l...
Introduction. Lung cancer is the most common cancer in the world. Every year, there are over 1.4 m...
Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. The last few years ha...
Trabalho Final do Mestrado Integrado em Medicina apresentado à Faculdade de MedicinaIntrodução: A de...
The disappointing results of long-term survival among patients with non-small cell lung cancer (NSCL...
AbstractWe report here a 66-year-old woman diagnosed with bronchioloalveolar carcinoma of the right ...
PURPOSE: Immune checkpoint inhibitors (ICI) have shown marked responses in patients with non-small c...
Objectives: Molecular diagnostics and care of non-small cell lung cancer (NSCLC) are continuously ev...
Introduction. Lung cancer is currently the most common malignancy (1.6 million new cases annually...
Aim: To evaluate treatment patterns and overall survival (OS) in real world metastatic non-squamous ...
The discovery of EGFR tyrosine kinase inhibitors (TKI) for the treatment of EGFR mutant (EGFRm) meta...